We also noted minimal changes in the ssGSEA score of two PI3K/AKT gene-sets on progression, with no evidence that PI3K/AKT activity was significantly changed from pre-therapy to disease progression even in the tumours carrying PI3K/AKT-activating alterations (including NRAS, KRAS mutations) (Fig. 1b). This evidence concerns the gene AKT1 and neoplasm.